


AMENDMENTS TO THE CLAIMS

1 (Currently Amended). A compound of the Formula I



Formula I

wherein:

R1 is NHR10, (substituted or unsubstituted C₁-C₆alkyl)NHR10 or (unsubstituted or substituted C₃-C₈ cycloalkyl)NHR10 wherein the substituted C₁-C₆ alkyl is substituted with one or more groups selected from: halo, hydroxyl, -OC₁-C₆ alkyl, cyano, SO₂(C₁-C₆ alkyl), OCF₃, CF₃, CONH₂, CON(CH₃)₂, or NO₂;

R10 is hydrogen, C₁-C₆alkyl, C₁-C₆alkyl(OH), C₁-C₆alkylidenyl(OH)R11, or an amino protecting group;

R11 is C₁-C₆alkyl, C₂-C₆alkenyl, C₁-C₆alkyl(O)C₁-C₆alkyl, C(O)O-C₁-C₆alkyl, aryl, or C₁-C₆alkylaryl;

R2 is hydrogen, C₁-C₆alkyl, aryl, or C₁-C₆alkylaryl;

R3 is unsubstituted or substituted aryl, unsubstituted or substituted C₁-C₆alkylaryl, unsubstituted or substituted C₁-C₆alkyl(O)-C₁-C₆alkylaryl, unsubstituted or substituted C₃-C₈ cycloalkyl, unsubstituted or substituted (C₁-C₆ alkyl) C₃-C₈ cycloalkyl, or indolinyl;

R4 is hydrogen, C₁-C₆alkyl, aryl, C₁-C₆alkylaryl, or C₂-C₆alkenyl;

R5 is hydrogen, aryl, C₁-C₆alkylaryl, hydroxy, C₁-C₆alkoxy, or unsubstituted or substituted C₁-C₆alkyl;

R6 and R7 are independently hydrogen, unsubstituted or substituted C₁-C₆alkyl, unsubstituted or substituted C₂-C₆alkenyl, or R6 and R7 together with the carbon atom to which they are attached form a carbocyclic ring of up to 8 atoms which is optionally partly unsaturated or a substituted C₃-C₈ cycloalkyl group which is optionally partly unsaturated;

R8 is hydrogen, unsubstituted or substituted C₁-C₆alkyl, unsubstituted or substituted aryl, unsubstituted or substituted (C₁-C₆alkyl)C₃-C₈cycloalkyl, or unsubstituted or substituted C₁-C₆alkylaryl;

R9 is hydrogen, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, C₃-C₈cycloalkenyl, cyano, unsubstituted or substituted aryl, unsubstituted or substituted -O-aryl, unsubstituted or substituted -N-aryl, unsubstituted or substituted -S-aryl, -aryl-aryl(K1)(K2), -O-aryl-aryl(K1)(K2), -N-aryl-aryl(K1)(K2), -S-aryl-aryl(K1)(K2), -O-C₁-C₆alkyl, or C₁-C₆alkylaryl, wherein K1 is halo or -CF₃, and K2 is hydrogen, halo or -CF₃; or K1 and K2 together form a methylenedioxy group;

Q is -S(O)₂- or -C(O)-; and

m is a number selected from 1 or 2;

provided that R1 is (substituted C₁-C₆alkyl)NHR10 or (unsubstituted or substituted C₃-C₈ cycloalkyl)NHR10; or

R5 is hydroxy, C₁-C₆alkoxy, or substituted C₁-C₆alkyl; or

R6 and R7 are independently unsubstituted or substituted C₁-C₆alkyl or unsubstituted or substituted C₂-C₆alkenyl with the proviso that at least one group is substituted; or


R6 is hydrogen and R7 is substituted C₁-C₆alkyl or substituted C₂-C₆alkenyl; or

R6 and R7 together with the carbon atom to which they are attached form a substituted C₃-C₈ cycloalkyl group which is optionally partly unsaturated; or

R8 is substituted C₁-C₆alkyl, substituted aryl, unsubstituted or substituted (C₁-C₆alkyl)C₃-C₈cycloalkyl or substituted C₁-C₆alkylaryl;

or a pharmaceutically acceptable salt thereof

2 (Currently Amended) A compound according to claim 1 having Formula I



Formula I

wherein:

R1 is NHR10 or C₁-C₆alkylNHR10;

R10 is hydrogen, C₁-C₆alkyl, C₁-C₆alkyl(OH), C₁-C₆alkylidenyl(OH)R11, or an amino protecting group;

R11 is C₁-C₆alkyl, C₂-C₆alkenyl, C₁-C₆alkyl(O)C₁-C₆alkyl, C(O)O-C₁-C₆alkyl, aryl, or C₁-C₆alkylaryl;

R2 is hydrogen, C₁-C₆alkyl, aryl, or C₁-C₆alkylaryl;

R3 is unsubstituted or substituted aryl, unsubstituted or substituted C₁-C₆alkylaryl, unsubstituted or substituted C₁-C₆alkyl(O)-C₁-C₆alkylaryl, unsubstituted or substituted C₃-C₈cycloalkyl, unsubstituted or substituted (C₁-C₆ alkyl) C₃-C₈ cycloalkyl, or indoliny;

R4 is hydrogen, C₁-C₆alkyl, aryl, C₁-C₆alkylaryl, or C₂-C₆alkenyl;

R5 is hydroxy, C₁-C₆alkoxy, or substituted C₁-C₆alkyl;

R6 and R7 are independently hydrogen, C₁-C₆alkyl, or C₂-C₆alkenyl, or R6 and R7 together with the carbon atom to which they are attached form a carbocyclic ring of up to 8 atoms which is optionally partly unsaturated;

R8 is hydrogen, C₁-C₆alkyl, aryl, or C₁-C₆alkylaryl;


R9 is hydrogen, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, C₃-C₈cycloalkenyl, cyano, unsubstituted or substituted aryl, unsubstituted or substituted -O-aryl, unsubstituted or substituted -N-aryl, unsubstituted or substituted -S-aryl, -aryl-aryl(K1)(K2), -O-aryl-aryl(K1)(K2), -N-aryl-aryl(K1)(K2), -S-aryl-aryl(K1)(K2), -O-C₁-C₆alkyl, or C₁-C₆alkylaryl, wherein K1 is halo or -CF₃, and K2 is hydrogen, halo or -CF₃ or K1 and K2 together form a methylenedioxy group;

Q is -S(O)₂- or -C(O)-;

m is a number selected from 1 or 2;

or a pharmaceutically acceptable salt thereof.

3 (Currently Amended). A compound according to claim 1 having Formula I



Formula I

wherein:

R1 is NHR10 or C₁-C₆alkylNHR10;

R10 is hydrogen, C₁-C₆alkyl, C₁-C₆alkyl(OH), C₁-C₆alkylidenyl(OH)R11, or an amino protecting group;

R11 is C₁-C₆alkyl, C₂-C₆alkenyl, C₁-C₆alkyl(O)C₁-C₆alkyl, C(O)O-C₁-C₆alkyl, aryl, or C₁-C₆alkylaryl;

R2 is hydrogen, C₁-C₆alkyl, aryl, or C₁-C₆alkylaryl;

R3 is unsubstituted or substituted aryl, unsubstituted or substituted C₁-C₆alkylaryl, unsubstituted or substituted C₁-C₆alkyl(O)-C₁-C₆alkylaryl, unsubstituted or substituted C₃-C₈cycloalkyl, unsubstituted or substituted (C₁-C₆ alkyl) C₃-C₈cycloalkyl, or indolyl;

R4 is hydrogen, C₁-C₆alkyl, aryl, C₁-C₆alkylaryl, or C₂-C₆alkenyl;

R5 is hydrogen, aryl, C₁-C₆alkylaryl, hydroxy, C₁-C₆alkoxy, or unsubstituted or substituted C₁-C₆alkyl;

R6 and R7 are independently hydrogen, C₁-C₆alkyl, or C₂-C₆alkenyl, or R6 and R7 together with the carbon atom to which they are attached form a carbocyclic ring of up to 8 atoms which is optionally partly unsaturated;

R8 is substituted C₁-C₆alkyl, substituted aryl, unsubstituted or substituted (C₁-C₆alkyl)C₃-C₈cycloalkyl or substituted C₁-C₆alkylaryl;

R9 is hydrogen, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, C₃-C₈cycloalkenyl, cyano, unsubstituted or substituted aryl, unsubstituted or substituted -O-aryl, unsubstituted or substituted -N-aryl, unsubstituted or substituted -S-aryl, -aryl-aryl(K1)(K2), -O-aryl-aryl(K1)(K2), -N-aryl-aryl(K1)(K2), -S-aryl-aryl(K1)(K2), -O-C₁-C₆alkyl, or C₁-C₆alkylaryl, wherein K1 is halo or -CF₃, and K2 is hydrogen, halo or -CF₃ or K1 and K2 together form a methylenedioxy group;

Q is -S(O)₂- or -C(O)-;

m is a number selected from 1 or 2;

or a pharmaceutically acceptable salt thereof.


unsubstituted or substituted -N-aryl, unsubstituted or substituted -S-aryl, -aryl-aryl(K1)(K2), -O-aryl-aryl(K1)(K2), -N-aryl-aryl(K1)(K2), -S-aryl-aryl(K1)(K2), -O-C₁-C₆alkyl, or C₁-C₆alkylaryl, wherein K1 is halo or -CF₃, and K2 is hydrogen, halo or -CF₃ or K1 and K2 together form a methylenedioxy group;

Q is -S(O)₂- or -C(O)-;

m is a number selected from 1 or 2;

or a pharmaceutically acceptable salt thereof.

5 (Currently Amended). A compound according to claim 1 having Formula I



Formula I

wherein:

R1 is (substituted C₁-C₆alkyl)NHR10 or (unsubstituted or substituted C₃-C₈ cycloalkyl)NHR10 wherein the substituted C₁-C₆ alkyl is substituted with one or more groups selected from: halo, hydroxyl, -OC₁-C₆ alkyl, cyano, SO₂(C₁-C₆ alkyl), OCF₃, CF₃, CONH₂, CON(CH₃)₂, or NO₂;

R10 is hydrogen, C₁-C₆alkyl, C₁-C₆alkyl(OH), C₁-C₆alkylidenyl(OH)R11, or an amino protecting group;

R11 is C₁-C₆alkyl, C₂-C₆alkenyl, C₁-C₆alkyl(O)C₁-C₆alkyl, C(O)O-C₁-C₆alkyl, aryl, or C₁-C₆alkylaryl;

R2 is hydrogen, C₁-C₆alkyl, aryl, or C₁-C₆alkylaryl;

R3 is unsubstituted or substituted aryl, unsubstituted or substituted C₁-C₆alkylaryl, unsubstituted or substituted C₁-C₆alkyl(O)-C₁-C₆alkylaryl, unsubstituted or substituted C₃-C₈ cycloalkyl, unsubstituted or substituted (C₁-C₆ alkyl) C₃-C₈ cycloalkyl, or indolyl;

R4 is hydrogen, C₁-C₆alkyl, aryl, C₁-C₆alkylaryl, or C₂-C₆alkenyl;

R5 is hydrogen, aryl, C₁-C₆alkylaryl, hydroxy, C₁-C₆alkoxy, or unsubstituted or substituted C₁-C₆alkyl;

R6 and R7 are independently hydrogen, unsubstituted or substituted C₁-C₆alkyl, or unsubstituted or substituted C₂-C₆alkenyl, or R6 and R7 together with the carbon atom to which they are attached form a carbocyclic ring of up to 8 atoms which is optionally partly unsaturated or a substituted C₃-C₈ cycloalkyl group which is optionally partly unsaturated;

R8 is hydrogen, unsubstituted or substituted C₁-C₆alkyl, unsubstituted or substituted aryl, unsubstituted or substituted (C₁-C₆alkyl)C₃-C₈cycloalkyl or unsubstituted or substituted C₁-C₆alkylaryl;

R9 is hydrogen, C₁-C₆alkyl, C₂-C₆alkenyl, C₂-C₆alkynyl, C₃-C₈cycloalkyl, C₃-C₈cycloalkenyl, cyano, unsubstituted or substituted aryl, unsubstituted or substituted -O-aryl, unsubstituted or substituted -N-aryl, unsubstituted or substituted -S-aryl, -aryl-aryl(K1)(K2), -O-aryl-aryl(K1)(K2), -N-aryl-aryl(K1)(K2), -S-aryl-aryl(K1)(K2), -O-C₁-C₆alkyl, or C₁-C₆alkylaryl, wherein K1 is halo or -CF₃, and K2 is hydrogen, halo or -CF₃ or K1 and K2 together form a methylenedioxy group;

Q is -S(O)₂- or -C(O)-;

m is a number selected from 1 or 2;

or a pharmaceutically acceptable salt thereof.

6 (Previously Presented). A compound according to claim 2 wherein R1 is



or a pharmaceutically acceptable salt thereof.

7 (Previously Presented). A compound according to claim 6 wherein R6 and R7 are each C₁-C₃ alkyl or form a five or six membered carbocyclic ring; or a pharmaceutically acceptable salt or thereof.

8 (Previously Presented). A compound according to claim 7 wherein R5 is hydroxy, C₁-C₆alkoxy, C₁-C₆alkyl which is substituted by hydroxy or C₁-C₆alkyl which is substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt thereof.

9 (Previously Presented). A compound according to claim 8 wherein R8 is hydrogen, methyl, ethyl or benzyl, or a pharmaceutically acceptable salt thereof.

10 (Previously Presented). A compound according to claim 3 wherein R1 is



or a pharmaceutically acceptable salt thereof.

11 (Previously Presented). A compound according to claim 10 wherein R6 and R7 are each C₁-C₃ alkyl or form a five or six membered carbocyclic ring, or a pharmaceutically acceptable salt thereof.

12 (Previously Presented). A compound according to claim 11 wherein R5 is hydrogen, C₁-C₆alkyl, C₁-C₆alkoxy, C₁-C₆alkyl which is substituted by hydroxy or C₁-C₆alkyl which is substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt thereof.

13 (Previously Presented). A compound according to claim 12 wherein R8 is C₁-C₆alkyl which is substituted by hydroxy or C₁-C₆alkyl which is substituted by one, two, or three halo atoms, phenyl substituted by one, two, or three halo atoms or benzyl substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt thereof.

14 (Previously Presented). A compound according to claim 4 wherein R1 is



or a pharmaceutically acceptable salt thereof.


15 (Currently Amended). A compound according to claim 14 wherein R6 and R7 are independently C₁-C₆alkyl or C₂-C₆alkenyl, in which one or both groups are substituted by one, two, or three halo atoms; or R6 is hydrogen and R7 is C₁-C₆alkyl, C₂-C₆alkenyl which is substituted by one, two, or three halo atoms; or R6 and R7 together with the carbon atom to which they are attached may form a C₃-C₈C₁-C₈cycloalkyl group which is optionally

partly unsaturated and which is substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt thereof.

16 (Previously Presented). A compound according to claim 15 wherein R5 is hydrogen, C₁-C₆alkyl, C₁-C₆alkoxy, C₁-C₆alkyl which is substituted by hydroxy or C₁-C₆alkyl which is substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt thereof.

17 (Previously Presented). A compound according to claim 16 wherein R8 is hydrogen, C₁-C₆alkyl, (C₁-C₆alkyl)C₃-C₈cycloalkyl, benzyl, 1-phenylethyl, C₁-C₆alkyl which is substituted by hydroxy, methoxy, CONH₂, or CON(CH₃)₂, or C₁-C₆alkyl which is substituted by one, two, or three halo atoms, phenyl substituted by one, two, or three halo atoms or benzyl substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt thereof.

18 (Previously Presented). A compound according to claim 5 wherein R1 is selected from -C(CH₃)(CH₂OH)NH₂, -C(CH₂F)₂NH₂, -C(CH₂F)(CH₂CH₂F)NH₂, -C(CF₃)(CH₃)NH₂, -C(CH₂CH₂F)₂NH₂, -C(CH₂CH₃)(CH₂CF₃)NH₂,



or a pharmaceutically acceptable salt thereof.


19 (Currently Amended). A compound according to claim 18 wherein R6 and R7 are each C₁-C₃ alkyl or form a five or six membered carbocyclic ring; or R6 and R7 are independently C₁-C₆alkyl or C₂-C₆alkenyl, in which one or both groups are substituted by one, two, or three halo atoms; or R6 is hydrogen and R7 is C₁-C₆alkyl, C₂-C₆alkenyl which is substituted by one, two, or three halo atoms; or R6 and R7 together with the carbon atom to which they are attached may form a C₃-C₈C₃-C₈cycloalkyl group which is optionally partly unsaturated and which is substituted by one, two, or three halo atoms; or a pharmaceutically acceptable salt thereof.

20 (Previously Presented). A compound according to claim 19 wherein R5 is hydrogen, C₁-C₆alkyl, C₁-C₆alkoxy, C₁-C₆alkyl which is substituted by hydroxy or C₁-

C₆alkyl which is substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt thereof.

21 (Previously Presented). A compound according to claim 20 wherein R₈ is hydrogen, C₁-C₆alkyl, benzyl, C₁-C₆alkyl which is substituted by hydroxy, C₁-C₆alkyl which is substituted by one, two, or three halo atoms, phenyl substituted by one, two, or three halo atoms or benzyl substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt thereof.

22 (Previously Presented). A compound according to claim 1 having Formula II



Formula II

wherein

R₁, R₂, R₃, R₅, R₆, R₇, R₈, R₉ and Q are as defined in claim 1 or a pharmaceutically acceptable salt thereof.

23 (Previously Presented). A compound according to claim 1 wherein R₃ is selected from unsubstituted or substituted aryl, unsubstituted or substituted C₁-C₆alkylaryl, unsubstituted or substituted C₁-C₆alkyl(O)-C₁-C₆alkylaryl, unsubstituted or substituted (C₁-C₆alkyl) C₃-C₈cycloalkyl; or a pharmaceutically acceptable salt thereof.

24 (Previously Presented). A compound according to claim 23 wherein the unsubstituted or substituted aryl group, unsubstituted or substituted C₁-C₆alkylaryl or unsubstituted or substituted C₁-C₆alkyl(O)-C₁-C₆alkylaryl group contains an aryl moiety selected from phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl optionally substituted by from one to three groups independently selected from C₁-C₆ alkyl, -

OC₁-C₆ alkyl, -OCF₃, amide, aryl, aryloxy, SO₂(C₁₋₆ alkyl), SO₂CF₃, NHamide, carboxamide, sulfonamide, Nhsulfonamide, imide, hydroxy, carboxy, nitro, halo, tri(chloro or fluoro)methyl, and cyano; or a pharmaceutically acceptable salt thereof.

25 (Previously Presented). A compound according to claim 1 wherein R₃ is an unsubstituted or substituted aryl group, an unsubstituted or substituted C₁-C₆ alkylaryl group or an unsubstituted or substituted C₁-C₆alkyl(O)- C₁-C₆alkyl aryl group wherein:

the C₁-C₆alkyl moiety within the unsubstituted or substituted C₁-C₆ alkylaryl group is methyl, ethyl or propyl;

the C₁-C₆alkyl(O)- C₁-C₆alkyl moiety within the unsubstituted or substituted C₁-C₆alkyl(O)- C₁-C₆alkyl aryl group is a moiety of formula -CH₂OCH₂-;

the unsubstituted or substituted aryl moiety is phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl which is unsubstituted or substituted by from one to three groups independently selected from halo, methyl, methoxy, cyano, SO₂Me, trifluoromethyl, and trifluoromethoxy or a pharmaceutically acceptable salt thereof.

26 (Previously Presented). A compound according to claim 1 wherein R₃ is selected from the group consisting of unsubstituted or substituted aryl, C₁-C₆alkylaryl, C₁-C₆alkyl(O)-C₁-C₆alkylaryl, C₃-C₈cycloalkyl, (C₁-C₆ alkyl) C₃-C₈cycloalkyl, indolyl, indoliny, or (C₁-C₆ alkyl) indolyl.

27 (Previously Presented). A compound according to claim 1 wherein R₄ is hydrogen or methyl, or a pharmaceutically acceptable salt thereof.


28 (Previously Presented). A compound according to claim 1 wherein R₉ is selected from the group consisting of unsubstituted or substituted thienyl, unsubstituted or substituted naphthyl, unsubstituted or substituted phenoxy and unsubstituted or substituted phenyl; wherein the substituents when present are each independently selected from the group consisting of halo, methyl, ethyl, propyl, t-butyl, trifluoromethyl, trifluoromethoxy, methoxy, ethoxy, cyano, methylsulphonyl, phenyl, phenoxy, thienyl, pyridyl, thiazolyl, oxazolyl, nitro, CONH₂, furanyl, benzothiophenyl and benzofuranyl; or a pharmaceutically acceptable salt thereof.

29 (Previously Presented). A compound of according to claim 28 wherein R9 is selected from phenyl, 4-methylsulphonylphenyl, 3-methylsulphonylphenyl, 4-fluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-chlorophenyl, 4-*t*-butylphenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-nitrophenyl, 3-nitrophenyl, 4-bromophenyl, 3-bromophenyl, 2-bromophenyl, 4-methylphenyl, 3-methylphenyl, 4-phenylphenyl, 3-phenylphenyl, 4-phenoxyphenyl, 3-phenoxyphenyl, 4-cyanophenyl, 3-cyanophenyl, 4-carbamoylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, thienyl, phenoxy, 4-chlorophenoxy, 2,3-dichlorophenyl, 3,4-dichlorophenyl, naphthyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3-difluorophenyl, 2,6-difluorophenyl, 2,5-difluorophenyl, 2-fluoro-3-chlorophenyl, 4-ethylphenyl, 4-ethoxyphenyl, 3,4,5-trifluorophenyl, 3-fluoro-4-chlorophenyl and 4-carbamoylphenyl; or a pharmaceutically acceptable salt thereof.


30 (Previously Presented). A pharmaceutical formulation comprising one or more compounds according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, and one or more pharmaceutically acceptable diluents or carriers therefor.

31 (Previously Presented). A pharmaceutical formulation according to claim 30 wherein the formulation further comprises one or more growth hormone secretagogue compounds and/or a bone-antiresorptive agent.

32 (Previously Presented). A process for producing a compound of Formula I as defined in claim 1 comprising coupling a compound of Formula XI or XIb




with a compound of formula XIII



XIII


wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and Q are as defined in claim 1.

33 (Previously Presented). A process for producing a compound of Formula I as defined in claim 1 comprising deprotecting a compound of Formula



wherein R2, R3, R4, R5, R6, R7, R8, R9, m and Q are as defined in claim 1, and PG is an amino protecting group.

34 (Previously Presented). A process for producing a compound of Formula I as defined in claim 1 comprising coupling a compound of Formula



with a compound of formula XIV

**XIV**

wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and Q are as defined in claim 1.

35 and 36 (canceled).

37 (Previously Presented). A method of treating a physiological condition which is modulated or ameliorated by an increase in endogenous growth hormone comprising administering an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof to an animal in need of said treatment.

38 (Previously Presented). A method of treating a condition selected from osteoporosis, physiological short stature caused by growth hormone deficiency, short stature associated with chronic illness, growth retardation associated with the Prader-Willi syndrome, intrauterine growth retardation, pulmonary dysfunction and ventricular dependency, insulin resistance, cachexia and protein loss due to cancer or AIDS comprising administering an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof to an animal in need of said treatment.

39 (Previously Presented). A compound selected from the group consisting of

2-(R)-2-(2-Amino-2-methylpropionylamino)-3- benzyloxy-propionic acid N-[5-(4-chlorophenyl)-2-cyclopropylmethyl-3,3-dimethyl-1,1-dioxo-2,3-dihydroisothiazol-4-ylmethyl]-N-ethylamide;

2-(R)-2-(2-Amino-2-methylpropionylamino)-3- benzyloxy-propionic acid N-[5-(4-chlorophenyl)- 3,3-dimethyl-1,1-dioxo-2-(2-methoxyethyl)-2,3-dihydroisothiazol-4-ylmethyl]-N-ethylamide;


2-(R)-2-(2-Amino-2-methylpropionylamino)-3- benzyloxy-propionic acid N-[5-(4-chlorophenyl)-3,3-dimethyl-1,1-dioxo-2-(2-fluoroethyl)-2,3-dihydroisothiazol-4-ylmethyl]-N-ethylamide;

2-(R)-2-(2-Amino-2-methylpropionylamino)-3- benzyloxy-propionic acid N-[5-(4-chlorophenyl)-3,3-dimethyl-1,1-dioxo-2-(4,4,4-trifluorobutyl)-2,3-dihydroisothiazol-4-ylmethyl]-N-ethylamide;

2-(R)-2-(2-Amino-2-methylpropionylamino)-3- benzyloxy-propionic acid N-[2-carbamoylmethyl-5-(4-chlorophenyl)-3,3-dimethyl-1,1-dioxo-2,3-dihydroisothiazol-4-ylmethyl]-N-ethylamide; and

2-(R)-2-(2-Amino-2-methylpropionylamino)-3- benzyloxy-propionic acid N-[5-(4-chlorophenyl)-3,3-dimethyl-2-(N',N'-dimethylcarbamoyl)methyl-1,1-dioxo-2,3-dihydroisothiazol-4-ylmethyl]-N-ethylamide;
or a pharmaceutically acceptable salt thereof.

40 (Previously Presented). A compound of the formula



wherein

X is O, Y is 4-Cl, Z is H and R5 is CH₂CH₃; or a pharmaceutically acceptable salt thereof.

41 (Previously Presented). A method for the treatment of a physiological condition which is modulated or ameliorated by an increase in endogenous growth hormone comprising administering an effective amount of a compound of claim 39 or a pharmaceutically acceptable salt to an animal in need of said treatment.


42 (Previously Presented). A method for treating a condition selected from osteoporosis, physiological short stature caused by growth hormone deficiency, short stature associated with chronic illness, growth retardation associated with the Prader-Willi syndrome, intrauterine growth retardation, pulmonary dysfunction and ventricular dependency, insulin resistance, cachexia and protein loss due to cancer or AIDS comprising administering an effective amount of a compound of claim 39 or a pharmaceutically acceptable salt to an animal in need of said treatment.

43 (Previously Presented). A method c thereof for the treatment of a physiological condition which is modulated or ameliorated by an increase in endogenous growth hormone comprising administering an effective amount of a compound of claim 40 or a pharmaceutically acceptable salt to an animal in need of said treatment.

44 (Previously Presented). A method for treating a condition selected from osteoporosis, physiological short stature caused by growth hormone deficiency, short stature associated with chronic illness, growth retardation associated with the Prader-Willi syndrome, intrauterine growth retardation, pulmonary dysfunction and ventricular dependency, insulin resistance, cachexia and protein loss due to cancer or AIDS comprising administering an effective amount of a compound of claim 40 or a pharmaceutically acceptable salt to an animal in need of said treatment.

45 (Previously Presented). A compound according to claim 2 having Formula

II



Formula II

wherein

R1, R2, R3, R5, R6, R7, R8, R9 and Q are as defined in claim 2 or a pharmaceutically acceptable salt thereof.

46 (Previously Presented). A compound according to claim 45 wherein R3 is selected from unsubstituted or substituted aryl, unsubstituted or substituted C₁-C₆alkylaryl, unsubstituted or substituted C₁-C₆alkyl(O)-C₁-C₆alkylaryl, or unsubstituted or substituted (C₁-C₆ alkyl) C₃-C₈ cycloalkyl; wherein the unsubstituted or substituted aryl group, unsubstituted or substituted C₁-C₆alkylaryl or unsubstituted or substituted C₁-C₆alkyl(O)-C₁-C₆alkylaryl group contains an aryl moiety selected from phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl optionally substituted by from one to three groups independently selected from C₁-C₆ alkyl, -OC₁-C₆ alkyl, -OCF₃, amide, aryl, aryloxy, SO₂(C₁₋₆ alkyl), SO₂CF₃, NHamide, carboxamide, sulfonamide, Nhsulfonamide, imide, hydroxy, carboxy, nitro, halo, tri(chloro or fluoro)methyl, and cyano; or a pharmaceutically acceptable salt thereof.

47 (Previously Presented). A compound according to claim 45 wherein R3 is an unsubstituted or substituted aryl group, an unsubstituted or substituted C₁-C₆alkylaryl group or an unsubstituted or substituted C₁-C₆alkyl(O)-C₁-C₆alkyl aryl group wherein: the C₁-C₆alkyl moiety within the unsubstituted or substituted C₁-C₆alkylaryl group is methyl, ethyl or propyl;

the C₁-C₆alkyl(O)-C₁-C₆alkyl moiety within the unsubstituted or substituted C₁-C₆alkyl(O)-C₁-C₆alkyl aryl group is a moiety of formula -CH₂OCH₂-;

the unsubstituted or substituted aryl moiety is phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl which is unsubstituted or substituted by from one to three groups independently selected from halo, methyl, methoxy, cyano, SO₂Me, trifluoromethyl, and trifluoromethoxy or a pharmaceutically acceptable salt thereof.


48 (Previously Presented). A compound according to claim 45 wherein R3 is selected from the group consisting of unsubstituted or substituted aryl, C₁-C₆alkylaryl, C₁-C₆alkyl(O)-C₁-C₆alkylaryl, C₃-C₈ cycloalkyl, (C₁-C₆ alkyl) C₃-C₈ cycloalkyl, indolyl, indolinyl, and (C₁-C₆ alkyl) indolyl.

49 (Previously Presented). A compound according to claim 45 wherein R9 is selected from the group consisting of unsubstituted or substituted thienyl, unsubstituted or substituted naphthyl, unsubstituted or substituted phenoxy and unsubstituted or substituted phenyl; wherein the substituents when present are each independently selected from the group consisting of halo, methyl, ethyl, propyl, t-butyl, trifluoromethyl, trifluoromethoxy, methoxy, ethoxy, cyano, methylsulphonyl, phenyl, phenoxy, thienyl, pyridyl, thiazolyl, oxazolyl, nitro, CONH₂, furanyl, benzothiophenyl and benzofuranyl; or a pharmaceutically acceptable salt thereof.

50 (Previously Presented). A compound of according to claim 49 wherein R9 is selected from phenyl, 4-methylsulphonylphenyl, 3-methylsulphonylphenyl, 4-fluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-chlorophenyl, 4-t-butylphenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-nitrophenyl, 3-nitrophenyl, 4-bromophenyl, 3-bromophenyl, 2-bromophenyl, 4-methylphenyl, 3-methylphenyl, 4-phenylphenyl, 3-phenylphenyl, 4-phenoxyphenyl, 3-phenoxyphenyl, 4-cyanophenyl, 3-cyanophenyl, 4-carbamoylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, thienyl, phenoxy, 4-chlorophenoxy, 2,3-dichlorophenyl, 3,4-dichlorophenyl, naphthyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3-difluorophenyl, 2,6-difluorophenyl, 2,5-difluorophenyl, 2-fluoro-3-chlorophenyl, 4-ethylphenyl, 4-ethoxyphenyl 3,4,5-trifluorophenyl, 3-fluoro-4-chlorophenyl and 4-carbamoylphenyl; or a pharmaceutically acceptable salt thereof.

51 (Previously Presented). A compound according to claim 3 having Formula

II



Formula II

wherein

R1, R2, R3, R5, R6, R7, R8, R9 and Q are as defined in claim 3 or a pharmaceutically acceptable salt thereof.

52 (Previously Presented). A compound according to claim 51 wherein R3 is selected from unsubstituted or substituted aryl, unsubstituted or substituted C₁-C₆alkylaryl, unsubstituted or substituted C₁-C₆alkyl(O)-C₁-C₆alkylaryl, or unsubstituted or substituted (C₁-C₆ alkyl) C₃-C₈ cycloalkyl; wherein the unsubstituted or substituted aryl group, unsubstituted or substituted C₁-C₆alkylaryl or unsubstituted or substituted C₁-C₆alkyl(O)-C₁-C₆alkylaryl group contains an aryl moiety selected from phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl optionally substituted by from one to three groups independently selected from C₁-C₆ alkyl, -OC₁-C₆ alkyl, -OCF₃, amide, aryl, aryloxy, SO₂(C₁₋₆ alkyl), SO₂CF₃, NHamide, carboxamide, sulfonamide, Nhsulfonamide, imide, hydroxy, carboxy, nitro, halo, tri(chloro or fluoro)methyl, and cyano; or a pharmaceutically acceptable salt thereof.

53 (Previously Presented). A compound according to claim 51 wherein R3 is an unsubstituted or substituted aryl group, an unsubstituted or substituted C₁-C₆alkylaryl group or an unsubstituted or substituted C₁-C₆alkyl(O)- C₁-C₆alkyl aryl group wherein:

the C₁-C₆alkyl moiety within the unsubstituted or substituted C₁-C₆ alkylaryl group is methyl, ethyl or propyl;

the C₁-C₆alkyl(O)- C₁-C₆alkyl moiety within the unsubstituted or substituted C₁-C₆alkyl(O)- C₁-C₆alkyl aryl group is a moiety of formula -CH₂OCH₂-;

the unsubstituted or substituted aryl moiety is phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl which is unsubstituted or substituted by from one to three groups independently selected from halo, methyl, methoxy, cyano, SO₂Me, trifluoromethyl, and trifluoromethoxycyanophenyl, 4-cyanophenyl, 4-methanesulphonylphenyl, and 2-methyl thiazolyl; or a pharmaceutically acceptable salt thereof.


54 (Previously Presented). A compound according to claim 51 wherein R3 is selected from the group consisting of unsubstituted or substituted aryl, C₁-C₆alkylaryl, C₁-C₆alkyl(O)-C₁-C₆alkylaryl, C₃-C₈ cycloalkyl, (C₁-C₆ alkyl) C₃-C₈ cycloalkyl, indolyl, indolinyl, or (C₁-C₆ alkyl) indolyl.

55 (Previously Presented). A compound according to claim 51 wherein R9 is selected from the group consisting of unsubstituted or substituted thienyl, unsubstituted or substituted naphthyl, unsubstituted or substituted phenoxy and unsubstituted or substituted phenyl; wherein the substituents when present are each independently selected from the group consisting of halo, methyl, ethyl, propyl, t-butyl, trifluoromethyl, trifluoromethoxy, methoxy, ethoxy, cyano, methylsulphonyl, phenyl, phenoxy, thienyl, pyridyl, thiazolyl, oxazolyl, nitro, CONH₂, furanyl, benzothiophenyl and benzofuranyl; or a pharmaceutically acceptable salt thereof.

56 (Previously Presented). A compound of according to claim 55 wherein R9 is selected from phenyl, 4-methylsulphonylphenyl, 3-methylsulphonylphenyl, 4-fluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-chlorophenyl, 4-t-butylphenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-nitrophenyl, 3-nitrophenyl, 4-bromophenyl, 3-bromophenyl, 2-bromophenyl, 4-methylphenyl, 3-methylphenyl, 4-phenylphenyl, 3-phenylphenyl, 4-phenoxyphenyl, 3-phenoxyphenyl, 4-cyanophenyl, 3-cyanophenyl, 4-carbamoylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, thienyl, phenoxy, 4-chlorophenoxy, 2,3-dichlorophenyl, 3,4-dichlorophenyl, naphthyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3-difluorophenyl, 2,6-difluorophenyl, 2,5-difluorophenyl, 2-fluoro-3-chlorophenyl, 4-ethylphenyl, 4-ethoxyphenyl 3,4,5-trifluorophenyl, 3-fluoro-4-chlorophenyl and 4-carbamoylphenyl; or a pharmaceutically acceptable salt thereof.

57 (Previously Presented). A compound according to claim 4 having Formula

II



Formula II

wherein

R1, R2, R3, R5, R6, R7, R8, R9 and Q are as defined in claim 4 or a pharmaceutically acceptable salt thereof.

58 (Previously Presented). A compound according to claim 57 wherein R3 is selected from unsubstituted or substituted aryl, unsubstituted or substituted C₁-C₆alkylaryl, unsubstituted or substituted C₁-C₆alkyl(O)-C₁-C₆alkylaryl, or unsubstituted or substituted (C₁-C₆ alkyl) C₃-C₈ cycloalkyl; wherein the unsubstituted or substituted aryl group, unsubstituted or substituted C₁-C₆alkylaryl or unsubstituted or substituted C₁-C₆alkyl(O)-C₁-C₆alkylaryl group contains an aryl moiety selected from phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl optionally substituted by from one to three groups independently selected from C₁-C₆ alkyl, -OC₁-C₆ alkyl, -OCF₃, amide, aryl, aryloxy, SO₂(C₁₋₆ alkyl), SO₂CF₃, NHamide, carboxamide, sulfonamide, Nhsulfonamide, imide, hydroxy, carboxy, nitro, halo, tri(chloro or fluoro)methyl, and cyano; or a pharmaceutically acceptable salt thereof.

59 (Currently Amended). A compound according to claim 57 wherein R3 is an unsubstituted or substituted aryl group, an unsubstituted or substituted C₁-C₆alkylaryl group or an unsubstituted or substituted C₁-C₆alkyl(O)-C₁-C₆alkyl aryl group wherein: the C₁-C₆alkyl moiety within the unsubstituted or substituted C₁-C₆ alkylaryl group is methyl, ethyl or propyl;

the C₁-C₆alkyl(O)-C₁-C₆alkyl moiety within the unsubstituted or substituted C₁-C₆alkyl(O)-C₁-C₆alkyl aryl group is a moiety of formula -CH₂OCH₂-;

the unsubstituted or substituted aryl moiety is phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl which is unsubstituted or substituted by from one to three groups independently selected from halo, methyl, methoxy, cyano, SO₂Me, trifluoromethyl, and trifluoromethoxy; or a pharmaceutically acceptable salt thereof.

60 (Previously Presented). A compound according to claim 57 wherein R3 is selected from the group consisting of unsubstituted or substituted aryl, C₁-C₆alkylaryl, C₁-C₆alkyl(O)-C₁-C₆alkylaryl, C₃-C₈ cycloalkyl, (C₁-C₆ alkyl) C₃-C₈ cycloalkyl, indolyl, indolinyl, or (C₁-C₆ alkyl) indolyl.

wherein

R1, R2, R3, R5, R6, R7, R8, R9 and Q are as defined in claim 5 or a pharmaceutically acceptable salt thereof.

64 (Previously Presented). A compound according to claim 63 wherein R3 is selected from unsubstituted or substituted aryl, unsubstituted or substituted C₁-C₆alkylaryl, unsubstituted or substituted C₁-C₆alkyl(O)-C₁-C₆alkylaryl, or unsubstituted or substituted (C₁-C₆ alkyl) C₃-C₈ cycloalkyl; wherein the unsubstituted or substituted aryl group, unsubstituted or substituted C₁-C₆alkylaryl or unsubstituted or substituted C₁-C₆alkyl(O)-C₁-C₆alkylaryl group contains an aryl moiety selected from phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl optionally substituted by from one to three groups independently selected from C₁-C₆ alkyl, -OC₁-C₆ alkyl, -OCF₃, amide, aryl, aryloxy, SO₂(C₁₋₆ alkyl), SO₂CF₃, NHamide, carboxamide, sulfonamide, Nhsulfonamide, imide, hydroxy, carboxy, nitro, halo, tri(chloro or fluoro)methyl, and cyano; or a pharmaceutically acceptable salt thereof.

65 (Currently Amended). A compound according to claim 63 wherein R3 is an unsubstituted or substituted aryl group, an unsubstituted or substituted C₁-C₆alkylaryl group or an unsubstituted or substituted C₁-C₆alkyl(O)-C₁-C₆alkyl aryl group wherein: the C₁-C₆alkyl moiety within the unsubstituted or substituted C₁-C₆ alkylaryl group is methyl, ethyl or propyl;

the C₁-C₆alkyl(O)-C₁-C₆alkyl moiety within the unsubstituted or substituted C₁-C₆alkyl(O)-C₁-C₆alkyl aryl group is a moiety of formula -CH₂OCH₂-;


the unsubstituted or substituted aryl moiety is phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl which is unsubstituted or substituted by from one to three groups independently selected from halo, methyl, methoxy, cyano, SO₂Me, trifluoromethyl, and trifluoromethoxy; or a pharmaceutically acceptable salt thereof.

66 (Previously Presented). A compound according to claim 63 wherein R3 is selected from the group consisting of unsubstituted or substituted aryl, C₁-C₆alkylaryl, C₁-C₆alkyl(O)-C₁-C₆alkylaryl, C₃-C₈ cycloalkyl, (C₁-C₆ alkyl) C₃-C₈ cycloalkyl, indolyl, indolinyl, or (C₁-C₆ alkyl) indolyl.

67 (Previously Presented). A compound according to claim 63 wherein R9 is selected from the group consisting of unsubstituted or substituted thienyl, unsubstituted or substituted naphthyl, unsubstituted or substituted phenoxy and unsubstituted or substituted phenyl; wherein the substituents when present are each independently selected from the group consisting of halo, methyl, ethyl, propyl, t-butyl, trifluoromethyl, trifluoromethoxy, methoxy, ethoxy, cyano, methylsulphonyl, phenyl, phenoxy, thienyl, pyridyl, thiazolyl, oxazolyl, nitro, CONH₂, furanyl, benzothiophenyl and benzofuranyl; or a pharmaceutically acceptable salt thereof.

68 (Previously Presented). A compound of according to claim 63 wherein R9 is selected from phenyl, 4-methylsulphonylphenyl, 3-methylsulphonylphenyl, 4-fluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-chlorophenyl, 4-t-butylphenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-nitrophenyl, 3-nitrophenyl, 4-bromophenyl, 3-bromophenyl, 2-bromophenyl, 4-methylphenyl, 3-methylphenyl, 4-phenylphenyl, 3-phenylphenyl, 4-phenoxyphenyl, 3-phenoxyphenyl, 4-cyanophenyl, 3-cyanophenyl, 4-carbamoylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, thienyl, phenoxy, 4-chlorophenoxy, 2,3-dichlorophenyl, 3,4-dichlorophenyl, naphthyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3-difluorophenyl, 2,6-difluorophenyl, 2,5-difluorophenyl, 2-fluoro-3-chlorophenyl, 4-ethylphenyl, 4-ethoxyphenyl 3,4,5-trifluorophenyl, 3-fluoro-4-chlorophenyl and 4-carbamoylphenyl; or a pharmaceutically acceptable salt thereof.

69 (Previously Presented). A compound according to claim 21 having Formula II



Formula II

wherein

R1, R2, R3, R5, R6, R7, R8, R9 and Q are as defined in claim 21 or a pharmaceutically acceptable salt thereof.

70 (Previously Presented). A compound according to claim 69 wherein R3 is selected from unsubstituted or substituted aryl, unsubstituted or substituted C₁-C₆alkylaryl, unsubstituted or substituted C₁-C₆alkyl(O)-C₁-C₆alkylaryl, or unsubstituted or substituted (C₁-C₆ alkyl) C₃-C₈ cycloalkyl; wherein the unsubstituted or substituted aryl group, unsubstituted or substituted C₁-C₆alkylaryl or unsubstituted or substituted C₁-C₆alkyl(O)-C₁-C₆alkylaryl group contains an aryl moiety selected from phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl optionally substituted by from one to three groups independently selected from C₁-C₆ alkyl, -OC₁-C₆ alkyl, -OCF₃, amide, aryl, aryloxy, SO₂(C₁₋₆ alkyl), SO₂CF₃, NHamide, carboxamide, sulfonamide, Nhsulfonamide, imide, hydroxy, carboxy, nitro, halo, tri(chloro or fluoro)methyl, and cyano; or a pharmaceutically acceptable salt thereof.

71 (Currently Amended). A compound according to claim 69 wherein R3 is an unsubstituted or substituted aryl group, an unsubstituted or substituted C₁-C₆alkylaryl group or an unsubstituted or substituted C₁-C₆alkyl(O)-C₁-C₆alkyl aryl group wherein:
the C₁-C₆alkyl moiety within the unsubstituted or substituted C₁-C₆alkylaryl group is methyl, ethyl or propyl;
the C₁-C₆alkyl(O)-C₁-C₆alkyl moiety within the unsubstituted or substituted C₁-C₆alkyl(O)-C₁-C₆alkyl aryl group is a moiety of formula -CH₂OCH₂-;
the unsubstituted or substituted aryl moiety is phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl which is unsubstituted or substituted by from one to three groups independently selected from halo, methyl, methoxy, cyano, SO₂Me, trifluoromethyl, and trifluoromethoxy;
or a pharmaceutically acceptable salt thereof.

72 (Previously Presented). A compound according to claim 69 wherein R3 is selected from the group consisting of unsubstituted or substituted aryl, C₁-C₆alkylaryl, C₁-C₆alkyl(O)-C₁-C₆alkylaryl, C₃-C₈ cycloalkyl, (C₁-C₆ alkyl) C₃-C₈ cycloalkyl, indolyl, indolinyl, or (C₁-C₆ alkyl) indolyl.

73 (Previously Presented). A compound according to claim 69 wherein R9 is selected from the group consisting of unsubstituted or substituted thienyl, unsubstituted or substituted naphthyl, unsubstituted or substituted phenoxy and unsubstituted or substituted phenyl; wherein the substituents when present are each independently selected from the group consisting of halo, methyl, ethyl, propyl, t-butyl, trifluoromethyl, trifluoromethoxy, methoxy, ethoxy, cyano, methylsulphonyl, phenyl, phenoxy, thienyl, pyridyl, thiazolyl, oxazolyl, nitro, CONH₂, furanyl, benzothiophenyl and benzofuranyl; or a pharmaceutically acceptable salt thereof.

74 (Previously Presented). A compound of according to claim 69 wherein R9 is selected from phenyl, 4-methylsulphonylphenyl, 3-methylsulphonylphenyl, 4-fluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-chlorophenyl, 4-t-butylphenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-nitrophenyl, 3-nitrophenyl, 4-bromophenyl, 3-bromophenyl, 2-bromophenyl, 4-methylphenyl, 3-methylphenyl, 4-phenylphenyl, 3-phenylphenyl, 4-phenoxyphenyl, 3-phenoxyphenyl, 4-cyanophenyl, 3-cyanophenyl, 4-carbamoylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, thienyl, phenoxy, 4-chlorophenoxy, 2,3-dichlorophenyl, 3,4-dichlorophenyl, naphthyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3-difluorophenyl, 2,6-difluorophenyl, 2,5-difluorophenyl, 2-fluoro-3-chlorophenyl, 4-ethylphenyl, 4-ethoxyphenyl 3,4,5-trifluorophenyl, 3-fluoro-4-chlorophenyl and 4-carbamoylphenyl; or a pharmaceutically acceptable salt thereof.